Risk factor
Very poor trading liquidity
Profitability factor
Slightly undervalued vs peers
About
Haleos Labs Limited, established in 1990 and headquartered in Hyderabad, India, focuses on the manufacture of active pharmaceutical ingredients (APIs) and their chemical intermediates. Primarily operating within India, the company produces a comprehensive range of these essential components for a wide array of therapeutic applications. Their product portfolio supports treatments for conditions such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia. Additionally, they supply APIs for antihistamines, diuretics, hair loss solutions, and ophthalmic preparations. Beyond its domestic operations, the company also engages in the international export of its pharmaceutical products. Notably, the firm, formerly known as SMS Lifesciences India Limited, officially adopted its current name, Haleos Labs Limited, in August 2025.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, 'cheap' on EV/EBITDA, tradin